INNOVATIVE METHOD OF IRON TO THE BODY DELIVERY
INCREASES IRON BIOAVAILABILITY (i.e. THERAPEUTIC EFFICIENCY)
MAKES SUCROSOMIAL® IRON SAFER: DOES NOT PENETRATE OR ACCUMULATE IN ENTEROCYTES AND DOES NOT CAUSE SIDE EFFECTS FROM THE GIT
The mechanisms of liposome assimilation were disclosed in a series of experimental and clinical studies carried out in the 1970-1980s. It was found that the transport of liposomes is carried out by specific enterocytes - M-cells, which control the intake of macromolecular complexes possessing antigenic properties heterogenous to the body, throughout the small intestine.
Mechanism of Sucrosomial® iron absorption
Upon entering into the gastrointestinal tract, Sucrosomial® Iron is not identified, as it is in the protective liposome environment.
After overcoming the gastric barrier, the nanomolecule reaches small intestine, where it is completely absorbed by a certain type of epithelial cell - M-cells. They absorb sucrosome by endocytosis while leaving the nanomolecule contents unchanged.
Then, through the basement membrane, the sucrosome is transferred to the macrophage, which, with lymph, delivers it to the liver.
In liver cells, sucrosomes are biodegraded and ferric iron is released, which is deposited in ferritin and is used later to build heme (in the bone marrow).
© 2026 
